How can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison?
In October 2024, Mtech Access were delighted to be joined by experts from Arcturis and Delta Hat for a live webinar, where:
- Dan Howard (Associate Director – Health Economics, Mtech Access) shared some of the challenges that our clients face when developing HTA-ready health economic models with limited clinical trial data
- Joseph O’Reilly (Principal Medical Statistician, Arcturis) introduced solutions to these challenges using RWD and RWE approaches
- Nick Latimer (Analyst, Delta Hat; Professor of Health Economics, University of Sheffield; former NICE Appraisal Committee member) discussed how RWE is assessed by HTA committees
- Samantha Gillard (Director – HTA, Mtech Access) facilitated the discussion and put your questions to our experts
Watch the recording:
During the webinar, the panellists explored:
- The evidence required for health economic modelling, with a focus on partitioned survival modelling for oncology
- Challenges posed by immature data or single-arm studies
- How RWD can fill the gap
- What RWD look like in practice
- How RWD and RWE can support the HTA process
- How RWD can be used to generate external control arms
- Using RWD in an HTA submission – the assessor’s perspective
Request a copy of the presentation slides
Please complete the form below to request a copy of the slides our experts presented in this webinar.
Listen to the podcast:
This episode is also available as a podcast. Listen below or search ‘Pharma Market Access Insights – from Mtech Access’ on Spotify, Apple Podcasts or Google Podcasts.
About our panel
Dan Howard (Associate Director – Health Economics, Mtech Access)
Dan has 10 years’ experience as a technical, hands-on health economist in both consulting and industry. He has specialised in oncology and rare disease modelling across a breadth of indications, and has led or contributed to over 20 HTA submissions. Dan is also experienced in the development of indirect treatment comparisons in the context of single-armed oncology trials, which are becoming all the more common with accelerated regulatory pathways and corresponding earlier reimbursement timelines. Dan has an MSc in Health Economics and Decision Modelling from the University of Sheffield and an MPhil in Neuroscience from the University of Manchester.
Joseph O’Reilly (Principal Medical Statistician, Arcturis)
As a member of the RWE team at Arcturis, Joe is responsible for the development and implementation of statistical solutions for clients and the advancement of internal research programmes to devise novel methods for observational clinical research. He has led projects developing external control arms from RWD, which have been used to support NICE HTA submissions. Prior to joining Arcturis, Joe was a post-doctoral Biostatistician and Epidemiologist in The Institute of Genetics and Cancer at the University of Edinburgh. Joe obtained his PhD in Bayesian method development from the University of Bristol.
Nick Latimer (Analyst, Delta Hat; Professor of Health Economics, University of Sheffield; former NICE Appraisal Committee member)
Nick is a former National Institute for Health and Care Excellence (NICE) Appraisal Committee member, who has authored five NICE Decision Support Unit (DSU) technical support documents related to survival analysis, treatment switching, and partitioned survival models.
In addition to his role at Delta Hat, Nick is a Professor of Health Economics at the University of Sheffield. His current work involves investigating the use of cancer registry datasets to estimate the comparative effectiveness of treatments.
Samantha Gillard (Director – HTA, Mtech Access)
Sam has 21 years’ experience within market access and health economics, and leads the Mtech Access HTA Team. Having worked with the majority of the top 25 pharma companies and numerous medical device companies, Sam understands the varied challenges in getting a product to market and can offer strategic advice across the product life cycle. Sam has worked across a wide range of disease areas, with particular expertise in oncology, diabetes, cardiology, wound care, hip replacement, transplantation, and psoriasis. Sam has a PhD in neuropharmacology from the University of London.
The Mtech Access Team were delighted to be presenting this webinar alongside colleagues from Arcturis and Delta Hat.
Arcturis use RWD and specialise in applying innovative RWE techniques to support the discovery and development of new medicines.
Delta Hat specialise in the technical aspects of evidence-based medicine and modelling, as well as acting as external reviewers for NICE and the Scottish Medicines Consortium (SMC).
Mtech Access are experts in preparing all aspects of HTA submission dossiers and health economic models.
